Eli Lilly & Co.
LLY NYS
Pharmaceuticals
Indianapolis, IN
Pharmaceuticals
Indianapolis, IN
| 2017 IW US 500 Rank | 51 |
| 2016 IW US 500 Rank | 57 |
| Executive 1 | David A. Ricks, Chairman; President |
| Executive 2 | Melissa S. Barnes, Senior Vice President; Chief Ethics Officer |
| 2016 Revenue (US$ Millions) | $21,222 |
| Revenue Growth (%) | 6.33% |
| 2015 Revenue (US$ Millions) | $19,959 |
| Net Income (US$ Millions) | $2,738 |
| Common Shares Outstanding (Millions) | 1,100.88 |
| Earnings Per Share (US$) | $2.58 |
| Price to Earnings Ratio | 32.53 |
| Total Equity (US$ Millions) | $14,008 |
| Return on Equity (%) | 18.79% |
| Long Term Debt (US$ Millions) | $8,368 |
| Debt to Equity Ratio (%) | 0.60% |
| Market Capitalization (US$ Millions) | $80,969 |
| Total Assets (US$ Millions) | $38,806 |
| Current Assets (US$ Millions) | $15,101 |
| Inventories (US$ Millions) | $3,562 |
| Current Liabilities (US$ Millions) | $10,987 |
| Cost Of Goods Sold (US$ Millions) | $5,655 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.61 |